Novo Nordisk set to launch price cut for insulin drug NovoLog after harsh criticism over prices in the US
September 9, 2019Sales and Marketing Novo Nordisk, NovoLog, insulin
Danish drug maker Novo Nordisk has said it will offer a generic version of NovoLog (insulin aspart) at a price …
Lilly’s LOXO-292 shrinks tumours in lung cancer trial
September 9, 2019Research and Development, Sales and Marketing Cancer, Eli Lilly, lung cancer, pharma
Eli Lilly has announced its experimental cancer drug LOXO-292, acquired in January, shrank tumours in almost 70% of advanced lung …
Age affects efficacy of immunotherapy treatments in breast cancer patients
September 9, 2019Research and Development, Sales and Marketing Cancer, breast cancer, pharma
Recent clinical trial data has shown that immune checkpoints blockade (ICB) therapy, designed to unleash a patient’s immune system to …
Trump’s FDA: Is the US regulator being steered by the President?
September 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Trump, US, drug safety, pharma
FDA activity has fallen under Donald Trump, with the number of warning letters issued by the regulator dropping by a …
4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine
September 9, 2019Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma
Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …
AstraZeneca’s Imfinzi combo tops chemotherapy in treatment-naive advanced lung cancer
September 9, 2019Sales and Marketing AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca has unveiled new Phase 3 data for its immunotherapy Imfinzi (durvalumab), showing that it achieved its primary endpoint when …
Top Ten most popular articles on Pharmafile.com this week
September 6, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Mylan, brexit
It’s Friday, meaning the weekend is within reach and it’s time for a rundown of the most popular articles on …
Roche celebrates European approval of Tecentriq combo in first-line lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq
Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …
Novartis’ Lucentis secures European approval for infants with rare eye disease
September 6, 2019Medical Communications, Sales and Marketing Europe, Lucentis, Novartis, eye disease, pharma
Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European …
Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Novartis, capmatinib, lung cancer, pharma
Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing …
View of pharma industry sinks to new low in US, poll reveals
September 6, 2019Medical Communications US, pharma
The public have always been reticent with their trust in the pharmaceutical industry, but that trust has hit an all-time …
Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal
September 5, 2019Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, KRAS, Lupin, collaboration, pharma
Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and …
Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis
September 5, 2019Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis
Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …
BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme
September 5, 2019Research and Development BMS, glioblastoma multiforme, opdivo, pharma
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the …
Cancer drugs have surged since the 80s to account for 1 in 4 FDA approvals, report reveals
September 5, 2019Research and Development, Sales and Marketing Cancer, FDA, US, pharma
The number of cancer drug approvals in the US has surged over the last decade to account for over one …
Ireland will not suffer immediate medicine shortages in event of no-deal Brexit, says health authority
September 5, 2019Medical Communications, Sales and Marketing England, Ireland, UK, brexit, pharma
Though MPs are moving forward with their plan to block UK Prime Minister Boris Johnson’s supposed no-deal Brexit from the …
Key legal considerations in accelerating pharma using artificial intelligence
September 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, artificial intelligence, pharma
Charlotte Walker-Osborn, Partner and International Technology Sector Head and Nabil Asaad, Senior Associate, Intellectual Property Law Group – both from …
FREE WEBINAR: Leveraging technology for optimal engagement
September 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, Webinar, Within3, pharma
Join Pharmafocus and Within3 for a special webinar event on Thursday, 19 September, for a session exploring the changing trends …
Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma
September 4, 2019Research and Development, Sales and Marketing EU, Europe, MSD, keytruda, pharma, renal cell carcinoma
The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the …
Ardelyx’s tenapanor combo meets all key goals at Phase 3 in hyperphosphatemia patients on dialysis
September 4, 2019Research and Development Ardelyx, pharma, tenapanor
Ardelyx has revealed that its small molecule, non-binder, phosphate absorption inhibitor tenapanor met all primary and key secondary endpoints at …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
